BackReviva Pharmaceuticals Holdings Overview

Reviva Pharmaceuticals Holdings Total Current Liabilities

Latest total current liabilities for RVPH: $6.1M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$6.12M
46.83% YoYΔ $-5.39M vs prior year quarter

Peer average

Loading

Reviva Pharmaceuticals Holdings Total Current Liabilities History

Loading

Reviva Pharmaceuticals Holdings vs. peers: Total Current Liabilities Comparison

Loading

Reviva Pharmaceuticals Holdings Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Reviva Pharmaceuticals Holdings (RVPH) FAQ

Reviva Pharmaceuticals Holdings's total current liabilities stands at $6.1M as of March 2026. That compares with $12M in the prior-year period — down 46.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Reviva Pharmaceuticals Holdings reported $6.1M in total current liabilities versus $12M a year earlier — a 46.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $12M in the prior-year period — down 46.8% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Reviva Pharmaceuticals Holdings's total current liabilities evolved across reporting periods, while the comparison chart places RVPH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Reviva Pharmaceuticals Holdings's reading of $6.1M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.